Mycophenolate Pharmacokinetics and Association with Response to Acute Graft-versus-Host Disease Treatment from the Blood and Marrow Transplant Clinical Trials Network

Biology of Blood and Marrow Transplantation

Volumn 16, Issue 3, 2010, Pages 421-429

  Jacobson, Pamala A ^a   Huang, Jiayin ^a,b   Wu, Juan ^c   Kim, Miae ^a   Logan, Brent ^d   Alousi, Amin ^e   Grimley, Michael ^f   Bolaños Meade, Javier ^g   Ho, Vincent ^h   Levine, John E ⁱ   Weisdorf, Daniel ^j  

^a UNIVERSITY OF MINNESOTA   (United States)

^b VERTEX PHARMACEUTICALS   (United States)

^c EMMES CORPORATION   (United States)

^d MEDICAL COLLEGE OF WISCONSIN   (United States)

^e UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^f TEXAS TRANSPLANT INSTITUTE   (United States)

^g JOHNS HOPKINS UNIVERSITY   (United States)

^h DANA FARBER CANCER INSTITUTE   (United States)

ⁱ UNIVERSITY OF MICHIGAN   (United States)

^j UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID DERIVATIVE; METHYLPREDNISOLONE; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; STEROID;

ACUTE GRAFT VERSUS HOST DISEASE; ADULT; AREA UNDER THE CURVE; ARTICLE; BIOPSY; BONE MARROW TRANSPLANTATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DOSAGE FORM COMPARISON; DRUG MEGADOSE; DRUG PROTEIN BINDING; GASTROINTESTINAL SYMPTOM; GRAFT SURVIVAL; HUMAN; OVERALL SURVIVAL;

ADRENAL CORTEX HORMONES; ADULT; AREA UNDER CURVE; COMMUNICABLE DISEASES; DRUG THERAPY, COMBINATION; GLUCURONIDES; GRAFT VS HOST DISEASE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; LIVER; LOWER GASTROINTESTINAL TRACT; MIDDLE AGED; MYCOPHENOLIC ACID; REMISSION INDUCTION; SKIN; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 75749125789     PISSN: 10838791     EISSN: 15236536     Source Type: Journal    
DOI: 10.1016/j.bbmt.2009.11.010     Document Type: Article

References (61)

1. Martin P.J., Schoch G., Fisher L., et al. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 76 (1990) 1464-1472
2. Cragg L., Blazar B.R., Defor T., et al. A randomized trial comparing prednisone with antithymocyte globulin/prednisone as an initial systemic therapy for moderately severe acute graft-versus-host disease. Biol Blood Marrow Transplant 6 (2000) 441-447
3. Van Lint M.T., Uderzo C., Locasciulli A., et al. Early treatment of acute graft-versus-host disease with high- or low-dose 6-methylprednisolone: a multicenter randomized trial from the Italian Group for Bone Marrow Transplantation. Blood 92 (1998) 2288-2293
4. Martin P.J., Nelson B.J., Appelbaum F.R., et al. Evaluation of a CD5-specific immunotoxin for treatment of acute graft-versus-host disease after allogeneic marrow transplantation. Blood 88 (1996) 824-830
5. Mayer J., Krejci M., Doubek M., et al. Pulse cyclophosphamide for corticosteroid-refractory graft-versus-host disease. Bone Marrow Transplant 35 (2005) 699-705
6. Carpenter P.A., Lowder J., Johnston L., et al. A phase II multicenter study of visilizumab, humanized anti-CD3 antibody, to treat steroid-refractory acute graft-versus-host disease. Biol Blood Marrow Transplant 11 (2005) 465-471
7. Patriarca F., Sperotto A., Damiani D., et al. Infliximab treatment for steroid-refractory acute graft-versus-host disease. Haematologica 89 (2004) 1352-1359
8. Lee S.J., Zahrieh D., Agura E., et al. Effect of up-front daclizumab when combined with steroids for the treatment of acute graft-versus-host disease: results of a randomized trial. Blood 104 (2004) 1559-1564
9. Berger M., Biasin E., Saglio F., et al. Innovative approaches to treat steroid-resistant or steroid-refractory GVHD. Bone Marrow Transplant 42 Suppl 2 (2008) S101-S105
10. Ho V.T., Zahrieh D., Hochberg E., et al. Safety and efficacy of denileukin diftitox in patients with steroid-refractory acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation. Blood 104 (2004) 1224-1226
11. Bolanos-Meade J., Jacobsohn D.A., Margolis J., et al. Pentostatin in steroid-refractory acute graft-versus-host disease. J Clin Oncol 23 (2005) 2661-2668
12. Levine J.E., Paczesny S., Mineishi S., et al. Etanercept plus methylprednisolone as initial therapy for acute graft-versus-host disease. Blood 111 (2008) 2470-2475
13. Basara N., Blau W.I., Romer E., et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD in bone marrow transplant patients. Bone Marrow Transplant 22 (1998) 61-65
14. Shapira M.Y., Resnick I.B., Dray L., et al. A new induction protocol for the control of steroid-refractory/dependent acute graft-versus-host disease with alefacept and tacrolimus. Cytotherapy 11 (2009) 61-67
15. Shaughnessy P.J., Bachier C., and Grimley M. e al. Denileukin diftitox for the treatment of steroid-resistant acute graft-versus-host disease. Biol Blood Marrow Transplant 11 (2005) 188-193
16. Alousi A.M., Weisdorf D.J., Logan B.R., et al. Etanercept, mycophenolate, denileukin, or pentostatin plus corticosteroids for acute graft-versus-host disease: a randomized phase 2 trial from the Blood and Marrow Transplant Clinical Trials Network. Blood 114 (2009) 511-517
17. Bullingham R.E., Nicholls A., and Hale M. Pharmacokinetics of mycophenolate mofetil (RS61443): a short review. Transplant Proc 28 (1996) 925-929
18. Staatz C.E., and Tett S.E. Clinical pharmacokinetics and pharmacodynamics of mycophenolate in solid organ transplant recipients. Clin Pharmacokinet 46 (2007) 13-58
19. Shipkova M., Strassburg C.P., Braun F., et al. Glucuronide and glucoside conjugation of mycophenolic acid by human liver, kidney and intestinal microsomes. Br J Pharmacol 132 (2001) 1027-1034
20. Bowalgaha K., and Miners J.O. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 52 (2001) 605-609
21. van Gelder T., Klupp J., Barten M.J., et al. Comparison of the effects of tacrolimus and cyclosporine on the pharmacokinetics of mycophenolic acid. Ther Drug Monit 23 (2001) 119-128
22. Bullingham R.E., Nicholls A.J., and Kamm B.R. Clinical pharmacokinetics of mycophenolate mofetil. Clin Pharmacokinet 34 (1998) 429-455
23. Jacobson P., Rogosheske J., Barker J.N., et al. Relationship of mycophenolic acid exposure to clinical outcome after hematopoietic cell transplantation. Clin Pharmacol Ther 78 (2005) 486-500
24. van Gelder T., Hilbrands L.B., Vanrenterghem Y., et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 68 (1999) 261-266
25. Weber L.T., Shipkova M., Armstrong V.W., et al. The pharmacokinetic-pharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German Study Group on Mycophenolate Mofetil therapy. J Am Soc Nephrol 13 (2002) 759-768
26. Hale M.D., Nicholls A.J., Bullingham R.E., et al. The pharmacokinetic-pharmacodynamic relationship for mycophenolate mofetil in renal transplantation. Clin Pharmacol Ther 64 (1998) 672-683
27. Le Meur Y., Buchler M., Thierry A., et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation. Am J Transplant 7 (2007) 2496-2503
28. Giaccone L., McCune J.S., Maris M.B., et al. Pharmacodynamics of mycophenolate mofetil after nonmyeloablative conditioning and unrelated donor hematopoietic cell transplantation. Blood 106 (2005) 4381-4388
29. van Gelder T., Silva H.T., de Fijter J.W., et al. Comparing mycophenolate mofetil regimens for de novo renal transplant recipients: the fixed-dose concentration-controlled trial. Transplantation 86 (2008) 1043-1051
30. Kuypers D.R., Claes K., Evenepoel P., et al. Clinical efficacy and toxicity profile of tacrolimus and mycophenolic acid in relation to combined long-term pharmacokinetics in de novo renal allograft recipients. Clin Pharmacol Ther 75 (2004) 434-447
31. Kuypers D.R., de Jonge H., Naesens M., et al. Current target ranges of mycophenolic acid exposure and drug-related adverse events: a 5-year, open-label, prospective, clinical follow-up study in renal allograft recipients. Clin Ther 30 (2008) 673-683
32. Kiberd B.A., Lawen J., Fraser A.D., et al. Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation. Am J Transplant 4 (2004) 1079-1083
33. van Gelder T. Mycophenolate blood level monitoring: recent progress. Am J Transplant 9 (2009) 1495-1499
34. Kiehl M.G., Shipkova M., Basara N., et al. Mycophenolate mofetil in stem cell transplant patients in relation to plasma level of active metabolite. Clin Biochem 33 (2000) 203-208
35. Przepiorka D., Weisdorf D., Martin P., et al. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 15 (1995) 825-828
36. Jacobson P.A., Green K.G., and Hering B.J. Mycophenolate mofetil in islet cell transplant: variable pharmacokinetics but good correlation between total and unbound concentrations. J Clin Pharmacol 45 (2005) 901-909
37. Jacobson P., El-Massah S.F., Rogosheske J., et al. Comparison of two mycophenolate mofetil dosing regimens after hematopoietic cell transplantation. Bone Marrow Transplant 44 (2009) 113-120
38. Ng J., Rogosheske J., Barker J., et al. A limited sampling model for estimation of total and unbound mycophenolic acid (MPA) area under the curve (AUC) in hematopoietic cell transplantation (HCT). Ther Drug Monit 28 (2006) 394-401
39. Jeong H., and Kaplan B. Therapeutic monitoring of mycophenolate mofetil. Clin J Am Soc Nephrol 2 (2007) 184-191
40. van Gelder T., Le Meur Y., Shaw L.M., et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Ther Drug Monit 28 (2006) 145-154
41. Knight S.R., and Morris P.J. Does the evidence support the use of mycophenolate mofetil therapeutic drug monitoring in clinical practice? A systematic review. Transplantation 85 (2008) 1675-1685
42. van Hest R.M., Hesselink D.A., Vulto A.G., et al. Individualization of mycophenolate mofetil dose in renal transplant recipients. Expert Opin Pharmacother 7 (2006) 361-376
43. Gaston R.S., Kaplan B., Shah T., et al. Fixed- or controlled-dose mycophenolate mofetil with standard- or reduced-dose calcineurin inhibitors: the Opticept trial. Am J Transplant 9 (2009) 1607-1619
44. van Hest R.M., Doorduijn J.K., de Winter B.C., et al. Pharmacokinetics of mycophenolate mofetil in hematopoietic stem cell transplant recipients. Ther Drug Monit 29 (2007) 353-360
45. Bornhauser M., Schuler U., Porksen G., et al. Mycophenolate mofetil and cyclosporine as graft-versus-host disease prophylaxis after allogeneic blood stem cell transplantation. Transplantation 67 (1999) 499-504
46. Jenke A., Renner U., Richte M., et al. Pharmacokinetics of intravenous mycophenolate mofetil after allogeneic blood stem cell transplantation. Clin Transplant 15 (2001) 176-184
47. Basara N., Blau W.I., Kiehl M.G., et al. Mycophenolate mofetil for the prophylaxis of acute GVHD in HLA-mismatched bone marrow transplant patients. Clin Transplant 14 (2000) 121-126
48. Nash R.A., Johnston L., Parker P., et al. A phase I/II study of mycophenolate mofetil in combination with cyclosporine for prophylaxis of acute graft-versus-host disease after myeloablative conditioning and allogeneic hematopoietic cell transplantation. Biol Blood Marrow Transplant 11 (2005) 495-505
49. Renner U., Platzbecker U., Freiderg-Richter J., et al. Intravenous mycophenolate mofetil (MMF) after allogeneic blood stem cell transplantation: results of a dose-finding study. [abstract]. Blood 94 (1999) 156a
50. Maris M.B., Niederwieser D., Sandmaier B.M., et al. HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with hematologic malignancies. Blood 102 (2003) 2021-2030
51. Okamura A., Yamamori M., Shimoyama M., et al. Pharmacokinetics-based optimal dose-exploration of mycophenolate mofetil in allogeneic hematopoietic stem cell transplantation. Int J Hematol 88 (2008) 104-110
52. Royer B., Larosa F., Legrand F., Gerritsen-van Schieveen P., Berard M., Kantelip J.P., et al. Pharmacokinetics of mycophenolic acid administered 3 times daily after hematopoietic stem cell transplantation with reduced-intensity regimen. Biol Blood Marrow Transplant 15 9 (2009) 1134-1139
53. Baudard M., Vincent A., Moreau P., et al. Mycophenolate mofetil for the treatment of acute and chronic GVHD is effective and well tolerated but induces a high risk of infectious complications: a series of 21 BM or PBSC transplant patients. Bone Marrow Transplant 30 (2002) 287-295
54. Maris M.B., Sandmaier B.M., Storer B., et al. Unrelated peripheral blood stem cell (PBSC) transplantation using nonmyeloablative conditioning and mycophenoate mofetil (MMF) TID results in high engraftment rates. [abstract]. Blood 104 (2004) 503a
55. Borrows R., Chusney G., Loucaidou M., et al. Mycophenolic acid 12-h trough level monitoring in renal transplantation: association with acute rejection and toxicity. Am J Transplant 6 (2006) 121-128
56. Kanou M., Usui T., Ueyama H., et al. Stimulation of transcriptional expression of human UDP-glucuronosyltransferase 1A1 by dexamethasone. Mol Biol Rep 31 (2004) 151-158
57. Cattaneo D., Perico N., Gaspari F., et al. Glucocorticoids interfere with mycophenolate mofetil bioavailability in kidney transplantation. Kidney Int 62 (2002) 1060-1067
58. Lam S., Partovi N., Ting L.S., et al. Corticosteroid interactions with cyclosporine, tacrolimus, mycophenolate, and sirolimus: fact or fiction?. Ann Pharmacother 42 (2008) 1037-1047
59. Jacobson P., Green K., Rogosheske J., et al. Highly variable mycophenolate mofetil bioavailability following nonmyeloablative hematopoietic cell transplantation. J Clin Pharmacol 47 (2007) 6-12
60. Filler G., Lepage N., Delisle N., and Mai I. Effect of cyclosporine on mycophenolic acid area under the concentration-time curve in pediatric kidney transplant recipients. Ther Drug Monit 23 5 (2001) 514-519
61. Filler G., Zimmering M., and Mai I. Pharmacokinetics of mycophenolate mofetil are influenced by concomitant immunosuppression. Pediatr Nephrol 14 2 (2000) 100-104